Related Experiment Videos
Glycoprotein IIb/IIIa antagonists--from bench to practice
1Department of Cardiovascular Medicine, Cleveland Clinic Foundation, OH 44195, USA.
Cellular and Molecular Life Sciences : CMLS
|April 20, 2002
Summary
Glycoprotein (GP) IIb/IIIa inhibitors are crucial for cardiovascular diseases, primarily by inhibiting platelet aggregation. While parenteral agents show benefits, oral forms have demonstrated significant toxicity, necessitating further research for safer alternatives.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Hematology
Background:
- The alphaIIb beta3 receptor is central to platelet aggregation and thrombosis.
- Glycoprotein (GP) IIb/IIIa inhibitors have been developed for cardiovascular diseases like acute coronary syndromes and stroke.
Purpose of the Study:
- To review the effects of GP IIb/IIIa inhibitors on platelet function and non-platelet effects.
- To analyze clinical outcomes of parenteral and oral GP IIb/IIIa inhibitors.
- To explore molecular mechanisms underlying inhibitor efficacy and toxicity.
Main Methods:
- Review of clinical studies on parenteral and oral GP IIb/IIIa inhibitors.
- Analysis of research on alphaIIb beta3 receptor function.
- Examination of molecular aspects of GP IIb/IIIa inhibition.
Main Results:
- Parenteral GP IIb/IIIa inhibitors show significant benefits in reducing ischemic complications after percutaneous intervention.
- Parenteral agents offer modest benefits in acute coronary syndromes.
- Oral GP IIb/IIIa inhibitors have shown increased mortality (toxicity) in clinical trials.
Conclusions:
- Understanding alphaIIb beta3 receptor function and GP IIb/IIIa inhibition mechanisms is key to explaining clinical inconsistencies and toxicity.
- Further research may lead to the development of novel agents with improved therapeutic benefits and safety profiles.